Home
Browse Guidelines
Expert Commentaries
Guideline Syntheses
Guideline Matrix
Guideline Resources
Compare Guidelines
Frequently Asked Questions
Submit Guidelines
About
myNGC

Announcements

April 16, 2012

Health Awareness Topics - April 2012



NGC Spotlight


New research review, clinician and consumer guides added! Visit the AHRQ Evidence Reports page for a listing of reports produced under AHRQ's Evidence-based Practice Program and Effective Health Care Program.

Conference News


The Guidelines International Network (G-I-N) Conference 2012, will be held August 22-25, 2012 in Berlin, Germany. Registration External Web Site Policy is now open.

U.S. Food and Drug Administration (FDA) Advisory


  • April 10, 2012: Birth Control Pills Containing Drospirenone External Web Site Policy: FDA has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills.Based on this review, FDA has concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other progestin-containing pills. FDA is adding information about the studies to the labels of drospirenone-containing birth control pills.

NGC's Sister Resources